What Is the Average Life Expectancy After a Liver Transplant?

Most people who receive a liver transplant today can expect to live well beyond a decade. Large modern cohorts show roughly 87% of recipients surviving at least one year, about 74% reaching the five-year mark, and around 61–65% living past ten years. Those numbers represent dramatic improvement over earlier eras of transplantation, and they continue to edge upward as surgical techniques, organ preservation, and post-transplant care advance. But “average” hides a lot of individual variation: the reason you needed a transplant, your age, the quality of the donor organ, and even your neighborhood can shift your personal outlook by years in either direction.

The Headline Numbers and How They Have Changed

The most commonly cited survival figures come from large registry analyses. A landmark single-center study of 4,000 consecutive transplants at the University of Pittsburgh reported patient survival of 79% at one year, 67% at five years, 57% at ten years, and 50% at fifteen years.¹ Those cases stretched back to the late 1980s, when immunosuppression protocols were still being refined and surgical mortality was higher.

More recent nationwide data paint a noticeably better picture. A large Dutch cohort analysis found one-year survival of roughly 87% for both men and women, five-year survival around 74%, and ten-year survival between 61% and 65%, with women doing slightly better at the decade mark.² The jump from about 79% to 87% at one year reflects improvements in organ allocation, better perioperative care, and more targeted immunosuppression rather than any single breakthrough. In practical terms, that means the transplant itself is safer than it used to be, and the gains ripple forward into longer survival.

Why the Original Liver Disease Matters

Not all liver diseases carry the same prognosis after transplant. The condition that destroyed your native liver shapes both the risk of the disease coming back and your vulnerability to other complications afterward.

Hepatitis C used to be one of the trickiest indications because the virus almost always reinfected the new liver, accelerating graft damage and shortening survival. That changed sharply with the arrival of direct-acting antiviral drugs. In the era before those medications, one-year graft survival for hepatitis C-positive recipients was about 89%; after those drugs became standard, it climbed to roughly 92%, and three-year survival jumped from about 78% to 84%. The improvement was nearly four times greater in hepatitis C patients than in those without the virus, effectively closing the survival gap.³ These newer antivirals are well-tolerated and short-course, making them practical even for patients with advanced liver disease.⁴

Alcohol-related liver disease is now one of the most common reasons for transplant worldwide. Survival after transplant for this indication is broadly similar to other causes of cirrhosis.⁵ One-year patient survival following early transplant for alcohol-related liver disease, even in patients with shorter abstinence periods, has been reported at 94–96%.⁶ The risk factor that most consistently shortens long-term survival in this group is returning to heavy drinking, which happens in roughly 10–50% of recipients depending on how relapse is defined. Those who relapse face higher rates of cardiovascular disease and new cancers, particularly of the lung and upper digestive tract.⁵

Fatty liver disease linked to metabolic syndrome (often called NASH) has risen sharply as a transplant indication. Short- and mid-term survival for NASH recipients is comparable to other causes, with five-year survival around 80–85%.⁷ The catch is that NASH patients tend to carry metabolic baggage: obesity, diabetes, high blood pressure. A “high-risk phenotype” combining those features with age over 60 pushed five-year survival down to about 72%, compared with 87% in NASH patients without those characteristics.⁷ Recipients transplanted for NASH-related cirrhosis also face an increased risk of recurrent liver disease and cardiometabolic complications over the longer term.⁸

For liver cancer, transplant can be curative when the tumor meets established size and number criteria, but recurrence occurs in roughly 8–20% of recipients and carries a poor prognosis when it does.⁹

How Recipient Age Shapes the Outlook

Older recipients face steeper odds. A population-based study found that in-hospital mortality risk for recipients over 70 was about four times higher than for those around 50, even after accounting for the severity of liver disease.¹⁰ A meta-analysis of transplants for fatty liver disease found that recipients older than 65 had about twice the mortality risk compared with those under 50.¹¹ This does not mean transplant is futile in older adults; many septuagenarians do well. It does mean that the average survival statistics you encounter reflect a population skewed toward people in their 50s and 60s, and your personal projection shifts depending on where you fall.

At the other end of the age spectrum, children tend to do better in the long run. Twenty-year patient survival following childhood liver transplant has been reported near 80%, and most reach normal adult height.¹² Among pediatric whole-liver recipients, children aged one to five had about a third less mortality risk than infants under one year old, and those aged six to ten had an even larger advantage.¹³ However, long-term follow-up of pediatric recipients shows that over a third develop chronic kidney problems or abnormal liver biochemistry by the 20-year mark, which raises questions about lifetime graft durability.¹²

The Donor Organ and How It Is Preserved

Where the liver comes from matters, too. Most transplanted livers come from donors declared brain-dead (DBD), but organs from donors after circulatory death (DCD) are increasingly used to expand the pool. DCD livers historically carried higher complication rates. One long-term analysis found that patient survival was lower in the DCD group at every time point out to 15 years (84% vs. 91% at one year, 54% vs. 67% at ten years), with much higher rates of biliary complications, especially a condition called ischemic cholangiopathy.¹⁴ A separate study reported that graft survival (as opposed to patient survival) was lower at five years for DCD versus DBD livers, though patient survival differences were not always significant because recipients could be re-transplanted.¹⁵

Machine perfusion, which keeps the donated liver warm and metabolically active outside the body rather than storing it on ice, is changing this picture. A recent analysis found that DCD livers preserved with normothermic machine perfusion had an 87% reduction in graft failure compared with those stored with traditional cold storage, and recipients had significantly lower mortality.¹⁶ National registry data confirm this trend: DCD livers preserved by machine perfusion showed improved one-year and three-year graft survival compared to cold-stored DCD livers.¹⁷ This technology has a dual benefit: it improves outcomes for marginal organs and it allows transplant teams to assess organ viability before committing to surgery, reducing the number of livers discarded unnecessarily.

Living-donor transplant deserves mention here. For patients on the waitlist with moderate disease severity, receiving a living-donor liver cut mortality by about a third compared with staying on the list, with the benefit kicking in at relatively low disease-severity scores.¹⁸ In the specific case of acute liver failure, patient and graft survival for living-donor and deceased-donor transplant were similar at five years.¹⁹

Long-Term Complications That Threaten Survival

Surviving the surgery and the first year is the steepest hurdle, but the threats shift as the years pass. In the short term, surgical complications and infections are the leading killers. Over the long term, the biggest drivers of mortality shift to infections, recurrence of the original liver disease, cardiovascular disease, and new cancers.²

Cardiovascular problems have become the leading cause of death after transplant, particularly in recipients who had advanced cirrhosis before surgery.²⁰ The immunosuppressive drugs that keep the body from rejecting the liver contribute to metabolic syndrome: weight gain, diabetes, high cholesterol, and high blood pressure all become more common after transplant. Diabetes and chronic kidney disease are especially frequent post-transplant complications and significantly compromise both patient and graft survival.²¹ Kidney toxicity from calcineurin-inhibitor immunosuppressants is a particularly stubborn problem that can erode outcomes years down the line.²²

New cancers are another major late threat. Transplant recipients face roughly twice the cancer rate of the general population, and their tumors tend to appear at younger ages, at more advanced stages, and with more aggressive behavior.²³ The overall incidence of new cancers after transplant ranges widely, but estimates put five-year rates around 10–15% and ten-year rates around 20–32%.²⁴ Skin cancers are the most common but do not generally shorten life. The dangerous ones are solid organ cancers and lymphoproliferative disorders, which together account for the majority of cancer-related deaths in this population.²⁵ Aggressive cancer screening starting a few years post-transplant is now considered essential, though specific protocols vary by center.

Chronic rejection, while less common than it once was thanks to modern immunosuppression, still causes graft damage in some recipients and can lead to graft failure requiring re-transplantation.²⁶

What Happens When a Transplant Fails

If the first liver graft fails, re-transplantation is sometimes possible but carries significantly worse outcomes. One large analysis reported one-year, five-year, and ten-year patient survival after re-transplant of about 61%, 54%, and 50%, well below the roughly 82%, 72%, and 67% seen after a first transplant at the same center.²⁷ Outcomes after re-transplant depend heavily on how urgently it is needed, the patient’s kidney function, and age. Five-year survival ranged from as low as 15% for those in the worst-risk category to 83% for those in the best, based on a combination of those factors.²⁷ One silver lining: when a graft fails very early from primary nonfunction (meaning it simply never started working), re-transplant outcomes tend to be better than when the graft fails gradually from chronic rejection or recurrent disease.

How Socioeconomic Factors and Race Affect Outcomes

Survival statistics are population averages, but they obscure real disparities. Recipients from socioeconomically deprived areas have modestly but significantly worse outcomes. One U.S. study found that those in the most deprived neighborhoods had about a 6% higher adjusted risk of death and graft failure compared with those in the least deprived areas, and this gap widened beyond the first post-transplant year.²⁸ Specific socioeconomic markers like lack of college education, having public insurance, and not working for income were each independently associated with worse patient and graft survival.²⁹

Racial disparities compound these effects. Black recipients have up to a 21% increased risk of post-transplant mortality, and children from socially deprived communities are twice as likely to be nonadherent with immunosuppressive medications, with up to a 32% higher rate of graft failure.³⁰ These differences are not biological; they reflect barriers to follow-up care, medication access, and social support. They also mean that the survival statistics you encounter in the literature may overestimate outcomes for people facing structural disadvantages and underestimate them for those with strong support systems and stable insurance.

Immunosuppression Minimization and Drug Weaning

The liver is more tolerant of immune mismatch than most transplanted organs. This has led researchers to experiment with gradually reducing or even stopping immunosuppressive drugs in stable, long-term recipients. Success rates vary widely: documented rejection during drug tapering occurs in anywhere from 12% to 76% of attempts, but the vast majority of those rejection episodes are mild and resolve when medication is resumed. Only two cases of graft loss from chronic rejection have been reported across all published weaning protocols.³¹

This matters for long-term survival because immunosuppressive drugs themselves cause many of the late complications described above: kidney damage, metabolic syndrome, and cancer susceptibility. If it were possible to safely taper or stop those drugs in even a fraction of recipients, the long-term complication profile could improve substantially. For now, drug minimization remains largely a research pursuit. Most transplant centers reduce doses over time but do not attempt full withdrawal outside clinical trials. Still, the fact that the liver seems to “teach” the immune system to accept it more readily than a transplanted kidney or heart is a genuinely encouraging feature of the biology.

Psychosocial Outcomes in Long-Term Survivors

Survival numbers capture whether someone is alive, not how they are living. A cross-sectional study of pediatric transplant recipients with functioning grafts at 20 years found that about three-quarters were in education, employment, or training, and substance abuse rates were lower than the national average.³² That sounds encouraging, but the same study found that only about a quarter of the cohort met a composite measure the authors called “meaningful survival,” which combined physical health, mental health, and social functioning. About a quarter had mental health disorders. The gap between “alive with a working liver” and “thriving across all dimensions of life” is wider than the survival statistics suggest, and this is an area where research is still trying to understand what interventions help most.